Abstract
Background Accurate, affordable, and rapid point-of-care (PoC) diagnostics are critical to the global control and management of the COVID-19 pandemic. The current standard for accurate diagnosis of SARS-CoV-2 is laboratory-based reverse transcription polymerase chain reaction (RT-PCR). Here, we report a preliminary prospective performance evaluation of the QuantuMDx Q-POC™ SARS CoV-2 RT-PCR assay.
Methods Between November 2020 and March 2021, we obtained 49 longitudinal nose and throat swabs from 29 individuals hospitalised with RT-PCR confirmed COVID-19 at St George’s NHS Foundation Trust, London (UK). In addition, we obtained 101 mid nasal swabs from healthy volunteers in June 2021. We then used these samples to evaluate the Q-POC™ SARS-CoV-2 RT-PCR assay. The primary analysis was to compare the sensitivity and specificity of the Q-POC™ test against a reference laboratory-based RT-PCR assay.
Results The overall sensitivity of the Q-POC™ test compared with the reference test was 96.88% (83.78%-99.92% CI) for a cycle threshold (Ct) cut-off value for the reference test of 35 and 80.00% (64.35% to 90.95% CI) without altering the reference test’s Ct cut-off value of 40.
Conclusions The Q-POC™ test is a sensitive, specific and rapid point-of-care test for SARS-CoV-2 at a reference Ct cut-off value of 35. The Q-POC™ test provides an accurate and affordable option for RT-PCR at point-of-care without the need for sample pre-processing and laboratory handling. The Q-POC™ test would enable rapid diagnosis and clinical triage in acute care and other settings.
Competing Interest Statement
JC, MS, KB, GM, DM, PS, CP, A-MC, ES, JM and CT are employees of QuantuMDx. SK and HMS are shareholders and SK is advisor to QuantuMDx. SK, HMS and EG are in receipt of funds from QuantuMDx to develop diagnostic technologies and assays (that have supported DJC). SK is also member of the Scientific Advisory Committee for the Foundation for Innovative New Diag-nostics (FIND), a not-for-profit organisation that produces global guidance on affordable diagnos-tics, views expressed here do not represent FIND. All other authors have no conflicts of interest to declare.
Clinical Trial
NCT04351646
Funding Statement
HMS is supported by the Wellcome Trust Institutional Strategic Support Fund [204809] awarded to St. George's University of London. The DARTS study was supported by a DFID/Wellcome Trust Epidemic Preparedness coronavirus grant [220764]. This work was also supported by the St George's Hospital Charity.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for clinical sample use at SGUL was provided by the Institutional Review Board as part of the "Development and Assessment of Rapid Testing for SARS-CoV-2 outbreak" (DARTS) study, sponsored by St George's Hospital NHS Foundation Trust (Integrated Research Application System project ID: 282104; South Central - Oxford C Research Ethics Committee reference: 20/SC/0171; registered at clinicaltrials.gov NCT04351646). All participants for this study were recruited following informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is present in the manuscript and supplementary material.
